Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

Abstract

ObjectiveRecent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease.Design and methodsA cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database.ResultsThe mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0–9.6 and 0.8–78.4, P=0.04 and P<0.0001 respectively).ConclusionCabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3–4 years is not associated with an increased risk of clinically significant valvular regurgitation.